
Agree Realty Corporation (ADC)
$
72.34
-0.68 (-0.94%)
Key metrics
Financial statements
Free cash flow per share
4.3515
Market cap
7.8 Billion
Price to sales ratio
11.3332
Debt to equity
0.5133
Current ratio
0.0436
Income quality
2.4940
Average inventory
0
ROE
0.0335
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. The company's stock is identified with the symbol 'ADC' in the market, reflecting its presence on the New York Stock Exchange. The company incurred an interest expense of $108,904,000.00 reflecting its debt servicing obligations, while the EBITDA is $543,265,000.00 a key indicator of the company's operational profitability. Additionally, the gross profit ratio is 0.88 highlighting the efficiency of the company's production and sales operations. The gross profit stands at $542,246,000.00 emphasizing the company’s profitability from core operations. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states, containing approximately 21.0 million square feet of gross leasable area, making it a significant player in the retail real estate sector. The stock is reasonably priced at $71.22 appealing to a broad range of investors. With an average trading volume of 1,000,725.00 the stock indicates moderate liquidity, allowing for active trading. The company, with a mid-range market capitalization of $7,804,548,763.00 is a steady performer in the market. It is a key player in the retail industry, contributing significantly to the overall market landscape, and it belongs to the Real Estate sector, driving innovation and growth. As such, Agree Realty Corporation plays an important role in the real estate investment trust segment, providing valuable investment opportunities while maintaining a robust portfolio of retail properties leased to reputable tenants.
Investing in Agree Realty Corporation (ADC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Agree Realty Corporation stock to fluctuate between $67.58 (low) and $79.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-11-05, Agree Realty Corporation's market cap is $7,804,548,763, based on 107,887,044 outstanding shares.
Compared to PROLOGIS, INC., Agree Realty Corporation has a Lower Market-Cap, indicating a difference in performance.
Agree Realty Corporation pays dividends. The current dividend yield is 4.20%, with a payout of $0.26 per share.
To buy Agree Realty Corporation (ADC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADC. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $617,095,000 | EPS: $1.79 | Growth: 5.29%.
Visit https://www.agreerealty.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $80.44 (2022-08-16) | All-time low: $52.69 (2023-10-30).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

zacks.com
Retail REITs like Agree Realty, Federal Realty and Urban Edge are thriving as tight supply, disciplined growth and necessity-driven tenants sustain stability.

globenewswire.com
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th

prnewswire.com
LAUSANNE, Switzerland , Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, November 10, 2025, at 8:30 a.m. EST to report financial results for the third quarter of 2025 and provide operational updates.

seekingalpha.com
AI-driven tech stocks dominate 2025 returns, leaving dividend and high-yield ETFs lagging due to limited AI exposure. REITs face mixed fortunes: ARE and DOC struggle with life science oversupply, while IVT, AMT, ADC, and VICI offer attractive dividend growth and value. My current buy list focuses on undervalued REITs and ETFs with strong dividend growth.

fool.com
You can attempt to buy dividend stocks in such a way that you collect dividends every month, or just buy some stocks that pay dividends monthly. Realty Income is a high-yield REIT with a long history of reliably paying monthly dividends.

prnewswire.com
LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November: Stephens Biotechnology Virtual Fireside Chats 2025Date: November 3, 2025 Presentation Time: 12:00 p.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Virtual There will not be a replay or transcript of the call.

newsfilecorp.com
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA. Defence's proprietary Accum® platform is engineered to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing a critical limitation of current ADCs and enabling higher potency with reduced off-target toxicity.

seekingalpha.com
Agree Realty Corporation (NYSE:ADC ) Q3 2025 Earnings Call October 22, 2025 9:00 AM EDT Company Participants Reuben Treatman - Senior Director of Corporate Finance Joey Agree - President, CEO & Director Peter Coughenour - CFO, Secretary & Investor Relations Professional Conference Call Participants Nicholas Joseph - Citigroup Inc., Research Division Michael Goldsmith - UBS Investment Bank, Research Division Jana Galan - BofA Securities, Research Division James Kammert - Evercore ISI Institutional Equities, Research Division Linda Yu Tsai - Jefferies LLC, Research Division Omotayo Okusanya - Deutsche Bank AG, Research Division William John Kilichowski - Wells Fargo Securities, LLC, Research Division Robert Stevenson - Janney Montgomery Scott LLC, Research Division Spenser Allaway - Green Street Advisors, LLC, Research Division Upal Rana - KeyBanc Capital Markets Inc., Research Division Eric Borden - BMO Capital Markets Equity Research Brad Heffern - RBC Capital Markets, Research Division Wesley Golladay - Robert W. Baird & Co. Incorporated, Research Division R.J.

zacks.com
The headline numbers for Agree Realty (ADC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.1 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to FFO of $1.03 per share a year ago.
See all news